Program
mizagliflozin
Also written as “Mizagliflozin”, “Mizagliflozin 5 mg” and “Mizagliflozin 10 mg”.
Its studies are mostly in Hypoglycemia, led by Vogenx.
Furthest: phase 2, since Sep 8, 20223 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vogenx | 31 open or running | phase 2since Sep 8, 2022 | Sep 8, 2022 | Oct 2027phase 2 · NCT07760961 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2022First study: phase 2 study in Postbariatric HypoglycemiaFirst studyNCT05541939 · 9 enrolled · United States
- Jan 31, 2023Phase 2 study in Postbariatric HypoglycemiaNCT05721729 · 15 enrolled · United States
- Aug 7, 2026Phase 2 study in Postbariatric HypoglycemiaNCT07760961 · 36 planned · United States
Ahead
- Oct 2027Primary completion: phase 2 study in Postbariatric HypoglycemiaNCT07760961
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07760961Postbariatric Hypoglycemia · United States | 2 | Recruiting | Oct 2027 | 36 |
| NCT05721729Postbariatric Hypoglycemia · United States | 2 | Completed | May 1, 2024 | 15 |
| NCT05541939Postbariatric Hypoglycemia · United States | 2 | Completed | Feb 17, 2023 | 9 |
How it is read
Names in the registry
- “Mizagliflozin”, 2 entries
- “Mizagliflozin 5 mg”, 1 entry
- “Mizagliflozin 10 mg”, 1 entry
Conditions, from the studies’ own filings
- Hypoglycemia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.